Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 97

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 97
---
 consent in writing to the selection of an alternative forum, the federal
district courts of the United States shall be the sole and exclusive forum for any claim asserting a cause of action arising under the
Securities Act (for the avoidance of any doubt, such provision does not apply to any claim asserting a cause of action arising under the
Exchange Act). Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities
Act actions. Accordingly, both U. S. state and federal courts have jurisdiction to entertain such claims. This choice of forum provision
may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees and may increase the costs associated with such lawsuits, which may discourage such lawsuits against us and
our directors, officers and employees. Alternatively, if a court were to find these provisions of the Articles inapplicable to, or unenforceable
in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such
matters in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or
otherwise acquiring any interest in our share capital shall be deemed to have notice of and to have consented to the choice of forum provisions
of the Articles described above. This provision would not apply to suits brought to enforce a duty or liability created by the Exchange
Act or any other claim for which the U. S. federal courts have exclusive jurisdiction.

The listing of our securities on Nasdaq
did not benefit from the process undertaken in connection with an underwritten initial public offering, which has resulted in diminished
investor demand, inefficiencies in pricing and a more volatile public price for our securities.

Our ordinary shares and warrants
are listed on Nasdaq under the symbols “ DRTS” and “ DRTSW,” respectively. Unlike an underwritten initial public
offering of our securities, the initial listing of our securities as a result of the Business Combination did not benefit from the following:

  the book-building process undertaken                                                                                           

  underwriter support to help                                                                 

Because there were no underwriters
engaged in connection with our Business Combination, prior to the opening of trading on the trading day immediately following the Closing
Date, there was no traditional “roadshow” or book building process, and no price at which underwriters initially sold shares
to the public to help inform efficient and sufficient price discovery with